Viral oncogene expression is insufficient for neoplastic transformation of human cells, so human papillomavirus (HPV)-associated cancers will also rely upon mutations in cellular oncogenes and tumor suppressors. However, it has been difficult so far to distinguish incidental mutations without phenotypic impact from causal mutations that drive the development of HPVassociated cancers. In this study, we addressed this issue by conducting a functional screen for genes that facilitate the formation of HPV E6/E7-induced squamous cell cancers in mice using a transposon-mediated insertional mutagenesis protocol.
Introduction
Although viral oncogenes are often necessary for carcinogenesis, they are not sufficient to cause cancer. Several approaches have sought to identify the cellular perturbations that facilitated the development of virally induced cancers. To this end, groups have extensively mapped cellular pathways reprogrammed by viral oncogenes (1) and sequenced cervical cancers as well as head and neck squamous cell cancers (HNSCC) that are frequently associated with human papillomavirus (HPV) infections (2) (3) (4) (5) . Together, these studies have identified mutations in and/or activation of genes, including NOTCH1, PIK3CA, PTEN, and KRAS, among others. However, these studies have primarily catalogued the mutations associated with HPV cancers and, therefore, cannot distinguish between incidental mutations with no phenotypic impact from causal mutations that mediate disease. For example, evidence supports conflicting functions of NOTCH1 as either a tumor suppressor or an oncogene based on the tissue context (6) (7) (8) . Furthermore, previous observations did not account for how additional driving mutations, which are commonly found in cancers, may affect the tissue-specific functions of these candidates. Finally, validation of these candidates may benefit from primary tumor models that better reflect the human condition (9) because previous reports using in vitro passaged cell models have shown contradictory observations for the same gene (10, 11) . By identifying and validating the genetic events that affect HPVpositive tumor growth in vivo, we will better prognose outcomes and tailor therapies accordingly.
Here, we used transposon-based insertional mutagenesis as a functional screen to identify cellular genes that promoted the growth of autochthonous HPV-positive tumors. We identified 39 candidate genes, of which Notch1 was frequently mutated. Forward and reverse genetic approaches revealed that gain or loss of Notch1 promoted tumorigenesis in the skin. Thus, by identifying candidates that promoted HPV-positive tumorigenesis, we observed that Notch1 functioned unlike a traditional oncogene or tumor suppressor where gain or loss of activity accelerated tumor growth.
Materials and Methods

Animals
All mice were maintained under specific pathogen-free conditions and used according to protocols approved by The University of Chicago (Chicago, IL) Institutional Animal Care and Use Committee and Institutional Biosafety Committee. KH mice expressing the K14-CreER tam transgene (12) and the Lox-StopLox-HPV-Luc (LSL-E6E7) transgene have been described previously (13) ; ref. 19) were purchased from The Jackson Laboratory. Details of mouse strains are described in the Supplementary Methods and Supplementary  Table S1 .
Carcinogenesis models
For skin carcinogenesis, 1 week after tamoxifen (tam) treatment, the dorsal surface of mice was shaved and 25 mg of 7,12-dimethylbenz(a)anthracene (DMBA) in 200 mL was topically administered. One week after DMBA treatment, 7.5 mg of 12-O-tetradecanoylphorbol-l3-acetate (TPA) in 200 mL was administered twice per week for 8 weeks. Papilloma formation was monitored twice per week. Papillomas greater than 2 mm in diameter were scored. For oral tumor carcinogenesis, mice were treated with tamoxifen and 1 week after 4-NQO treatment was initiated at 20 mg/mL in drinking water. 4-NQO water was replaced weekly.
Sleeping Beauty transposon mapping and identification of common insertion sites
Transposon mapping was adapted from a previously reported protocol using ligation-mediated PCR with modifications described in the Supplementary Methods (16) . Supplementary  Table S2 lists primers used in Sleeping Beauty (SB) transposon mapping and used to make pooled PCR libraries that were sequenced using an Illumina HiSeq2500 (single-end 100 bp) runs at University of Chicago Functional Genomics Facility using standard methods. Sequencing reads were preprocessed to remove 5 0 transposon tag, 3 0 adaptor sequences, and 3 0 low-quality bases (base quality<20) using Cutadapt 1.1 and eliminated final reads shorter than 36 bp. We mapped preprocessed reads to the mm9 mouse genome assembly using Novoalign 3.00.05, allowing one best match per read. We removed reads with mapping quality lower than 20, reads with target sequences lacking the 5 0 TA transposon insertion site, and reads that mapped to the donor chromosome. We used the final reads to identify significant CIS using the TapDance pipeline (20) . Genomic regions significantly enriched with CIS were identified across samples by a sliding window approach, which applies Poisson distribution statistics normalized by the genome size, total number of events (insertions), and the observed integrations within a defined window. The identified significant CIS were annotated with nearby genes located within a maximum of 20,000 bp in distance.
Tumor growth measurements
Tumors were measured every 3 days as previously described (13) . We measured the intercommissural distance (a), two additional orthogonal measurements (b and c), and the lip thickness on each side (d and e) to calculate the oral tumor volume (mm 3 ) using the equation:
Immunohistochemistry and immunofluorescence
Tumors were isolated and placed into 10% formalin solution for 24 hours and then dehydrated with 70% ethanol. Tissues were processed and stained with hematoxyalin and eosin or the indicated antibodies at the University of Chicago Immunohistochemistry core facility. Histology was reviewed by a board-certified pathologist (M.W. Lingen). For immunofluorescence, tissues were embedded in optimal cutting temperature and immediately frozen in dry ice/2-methylbutane. Immunofluroescence images were captured on a Zeiss Axiovert 200M. We used a modified ImmunoRatio (21) Plugin installed in the ImageJ to quantify Hes1, Hey1, or bromodeoxyuridine (BrdUrd)-positive nuclei. The percentage of positively stained nuclei was assessed using a color deconvolution algorithm and adaptive threshold for nuclei area segmentation.
Microarrays
Tissues were snap-frozen in TRIzol (Invitrogen) and stored at À80 C until use. RNA was prepared and treated with DNAse (Thermo Scientific). Four to six distinct tumors were used per group covering two to three independent experiments. RNA quality was checked using an Agilent Bioanalyzer and biotinlabeled using an Illumina TotalPrep-96 RNA Amplification Kit (Illumina). RNA expression detection was performed using the Illumina Mouse Ref-8 v2 BeadChip (Illumina). Microarrays were scanned using an Illumina HiScan. Raw signal intensities of each probe were obtained using data analysis software (Genome Studio; Illumina) and imported into Partek after quantile normalization and background subtraction. Differentially expressed genes were identified using analysis of variance (ANOVA) model. We filtered differentially expressed genes with ! AE 2.0-fold change and an FDR < 0.05. Gene-specific expression analysis was performed using the Gene Set Enrichment Analysis (GSEA) package (22) . Pathway analysis on differentially expressed genes and CIS were assessed using Ingenuity Pathway Analysis (IPA). Microarray data have been deposited in Gene Expression Omnibus (Accession numbers GSE59950 and GSE59951).
Quantitative RT-PCR
Total RNA was isolated using TRIzol (Invitrogen), and treated with DNase I. cDNA was generated using the ProtoScript First Strand cDNA Synthesis Kit (NEB) and subjected to qPCR using SYBR Green Supermix (Bio-Rad). RT-PCR primer pairs for Mmp3, Mmp9, Mmp10, Mmp11, Mmp13, Twist2, and Col1a1 were obtained from Bio-Rad. qPCR reactions were run on an iQ 5 Multicolor Real-time QPCR Detection System Machine (Bio-Rad). C T values for individual samples were subtracted from the corresponding C T values for Gapdh (DC T ). Normalized fold expression was obtained using the Àlog 2 DDC T formula.
Notch1 expression in clinical samples
For cervical and breast cancer database analysis, Notch1, Hes1, and Hey1 expression data were downloaded from Oncomine (Life Technologies) using the Zhai cervix database (n ¼ 37) and the Curtis breast database (n ¼ 211). Notch1 expression in verrucous and invasive HNSCCs was conducted on prospectively acquired specimens in accordance with the University of Chicago IRB14-0729. IHC scoring was performed on a scale of 0 to 3þ for intensity. Notch expression was grouped into negative expression (0-1þ) and positive expression (2þ to 3þ). All histologic diagnosis and IHC expression was assessed by a single pathologist (M.W Lingen). Only patients with documented pathologies were included in analyses.
Statistical and database analysis
Besides statistical analysis of microarray and insertional mutagenesis experiments described elsewhere, statistical analysis was performed using JMP version 10 (SAS Institute). All tests to determine statistical significance were two-sided and statistical significance was defined as P < 0.05. Survival curves were plotted using the Kaplan-Meier method and comparisons between categorical risk factors were conducted using the logrank test. The x 2 test was used to compare differences between discrete variables, and the t test was used to compare continuous variables. Differences between medians were assessed using the Wilcoxon test.
Results
Sleeping Beauty transposon-based insertional mutagenesis accelerated HPV-positive carcinogenesis
Because additional cellular mutations likely cooperate with HPV oncogenes to cause cancer, we used SB transposon-based insertional mutagenesis that has identified candidate cancer genes in other models (14, 16, 23, 24) . To study HPV carcinogenesis, we used transgenic mice to conditionally express the HPV16 oncogenes E6 and E7 as well as SB transposition in the skin. We bred KH mice, containing the K14-CreER tam and LoxP-STOP-LoxP (LSL)-E6E7 transgenes (13) , to Onc mice, containing a Creregulated LSL-SB11 transgene (16) and a T2/Onc transposon transgene (KH Â Onc2 and KH Â Onc3 mice; Fig. 1A ; refs. 14, 15). Tamoxifen treatment of KH Â Onc mice activated the CreER tam transgene expressed in basal keratinocytes to excise the inhibitory LSL sequences to induce expression of HPV oncogenes and SB-transposition. As controls, we used K Â Onc (K Â Onc2 and K Â Onc3) mice that only induced SB transposition in the skin as well as KH mice.
To assess the impact of insertional mutagenesis on HPV oncogenesis, we treated mice with DMBA/TPA to accelerate skin tumorigenesis (Fig. 1A) . Papillomas occurred earlier in KH Â Onc mice compared with control K Â Onc mice and KH mice (P < 0.0001; Fig. 1B) . Furthermore, more papillomas developed in KH Â Onc mice (P < 0.0001) compared with K Â Onc mice or KH mice. For KH Â Onc tumors, 70.7% (n ¼ 29) were invasive cancers, 4.9% (n ¼ 2) were verrucous carcinomas, and 24.4% (n ¼ 10) were noninvasive lesions ( Fig. 1D and E) . The majority of tumors displayed SB-mediated transposition and HPV oncogene recombination ( Supplementary Fig. S1A ). From 150 KH Â Onc tumors treated with DMBA/TPA, 145 tumors (96.7%) contained a recombined LSL-E6E7oncogene, indicating HPV oncogene expression, and 119 tumors (79.3%) contained SB-excision at the donor chromosome ( Supplementary Fig. S1A and S1B). As DMBA induces Hras Q61K mutations, we found that 98.0% of tumors (n ¼ 147) tumors contained this mutation.
In a second carcinogenesis model, we used 4-NQO to induce oral tumors ( Supplementary Fig. S2A ). Compared with control KH Â Onc mice that did not receive tamoxifen, both KH Â Onc mice (P ¼ 0.003) and K Â Onc mice (P ¼ 0.005) more frequently developed oral tumors ( Supplementary Fig. S2B ). Seventy-seven percent of oral tumors were invasive squamous cell carcinomas, whereas the remainders were premalignant lesions or normal tissue (Supplementary Fig. S2C and S2D ). Thus, in two distinct HPV models, we have used insertional mutagenesis in order to accelerate tumor development.
Identification of CIS in HPV-positive and HPV-negative tumors
To identify transposon insertions, we applied a high-throughput analysis to map T2/Onc transposon integration sites in mutagenized tumors (16) . In DMBA/TPA-treated mice, we isolated T2/Onc integration sites from 69 KH Â Onc tumors and three K Â Onc tumors. In 4-NQO-treated mice, we isolated T2/ Onc integration sites from 27 KH Â Onc tumors and 15 K Â Onc tumors. High-throughput sequencing of pooled libraries resulted in 12,706,111 reads that were successfully mapped to the mouse genome and were used for identification of common insertion sites (CIS). In total, 39 significant regions were identified in both carcinogenesis models ( Fig. 2 and Supplementary Table S3 ). Fifty coding genes were within these regions, of which 39 genes possessed transposon insertions. Of these 39 genes only two, Notch1 and Gphn, were orthologous with known cancer-associated genes as determined by the Cancer Gene Consensus. Thus, we have identified several known and novel candidate genes involved in HPV carcinogenesis, of which some human orthologs possess were cancer-associated genes.
Notch1 contained transposon insertions with opposing orientations that correlated with heterogeneous gene expression
In both DMBA/TPA and 4-NQO models, Notch1 was located in one of the most significant CIS regions identified. Table S5 summarizes the transposon insertion frequency and orientation for genes in Fig. 3B . Using PCR to amplify the transposon-gene junction, we confirmed that these Notch1 insertions were tumor specific in 15 KH Â Onc3 tumors tested (Fig. 3C ).
Previous studies (14, 23) have used these transposon orientations to infer gene function because the transposon payload has a directional promoter and polyadenlyation site that respectively induces or inhibits gene expression depending on the orientation of the transposon insertion. Here, we observed that in DMBA/ TPA-treated tumors, transposons were oriented to induce Notch1 expression in 14 distinct tumors as well as to inhibit Notch1 expression in 12 tumors ( Table  S4 ; Supplementary Fig. S3 ). In contrast, in tumors with transposons oriented to inhibit gene expression, we detected decreased Notch1 mRNA expression and less intense Notch1 staining in tissue sections. Thus, even though the Notch1 pathway was a significant target for insertional mutagenesis, transposon insertions were predicted to induce and to inhibit Notch1 activity.
Activated Notch1 accelerated HPV-positive primary oral tumor growth
Given that tumor development was associated with transposon insertions predicted to upregulate Notch1 expression, we assessed the impact of Notch1 activation on HPV tumor growth. To account for the role of Hras mutations during HPV tumorigenesis, we used a KHR oral tumor model (13) where a tamoxifenregulated Cre recombinase drives HPV and Kras G12D oncogene expression in the epidermis and reflects the KRAS mutations that have been identified in HPV-associated cancers (3, 5) . We generated KHR mice containing a LSL-Rosa NICD transgene (18) , where the expression of the active Notch1 intracellular domain (NICD) was also dependent on Cre recombinase (KHR NICD mice). After tamoxifen treatment, KHR NICD oral tumors expressed the NICD transgene ( Supplementary Fig. S4 ). KHR NICD oral tumors grew faster compared with control KHR mice or KH NICD mice (Fig. 4A) . Similarly, anal tumors were larger in KHR NICD mice (18.2 AE 0.7 mm 2 ) compared with KHR mice (11.4 AE 0.5 mm 2 ; P < 0.0001) or KH NICD mice (5.6 AE 0.9 mm 2 ; P < 0.0001; Fig. 4B ). Furthermore, compared with KHR mice, KHR NICD tumors possessed increased nuclear localization for the Notch1 transcriptional targets Hey1 and Hes1 ( Fig. 4C and Supplementary Fig. S5 ).
Because NICD overexpression regulated basal cell differentiation (25), we assessed tumor cell proliferation and differentiation markers in oral tumors. Using BrdUrd incorporation to assess proliferation, KHR NICD oral tumors contained more BrdUrd-positive cells compared with KHR oral tumors (29.8% AE 5.6% vs. 19.8% AE 5.2%; P < 0.0001; Fig. 4D and E). KHR NICD anal tumors also contained more BrdUrd-positive cells compared with KHR Verrucous carcinoma (n = 2) 
, and KH Â Onc3 mice (n ¼ 33). C, mice expressing HPV oncogenes and undergoing insertional mutagenesis developed more papillomas ( Ã , P < 0.0001). Data displayed in quantile box-and-whisker plots where upper and lower whiskers represent the first and fourth quartiles, respectively, and the upper and lower boxes represent the second and third quartiles, respectively. D, histology of papillomas developing in KH Â Onc mice. Left scale bar, 500 mm; right scale bar, 100 mm. Box in lower magnification field area depicted in the higher magnification field. E, summary of histologic types of papillomas arising in KH Â Onc mice.
anal tumors (27.5% AE 5.5% vs. 19.2% AE 5.2%; P < 0.0001). Consistent with increased BrdUrd incorporation in KHR NICD tumors, gene enrichment analysis revealed that KHR NICD tumors were enriched in genes associated with in DNA replication and cell-cycle mitosis (Fig. 4F) . Although KHR tumors already displayed impaired differentiation as demonstrated by CK14 expression throughout the epithelial layers, expression of NICD did not further impact tumor differentiation as measured by CK14 intensity ( Fig. 4G and Supplementary Fig. S6 ). Thus, expression of activated Notch1 accelerated the growth of tumors displaying impaired differentiation profiles, indicating that Notch1 possessed oncogenic activities in primary HPV tumors. Mmp3, Mmp9, and Mmp13 were upregulated in KR-N À/À but not KR-N þ/À or KR tumors (Fig. 6D) . Furthermore, Notch1 activation resulted in downregulation of Mmp9, Mmp10, and Mmp13 in KHR NICD tumors compared with KHR tumors (Fig. 6E) . Thus, HPV oral tumors with haploinsufficiency or complete loss of Notch1 had increased expression of genes associated with invasion.
Although tumors with either intact or deficient Notch1 displayed evidence of invasion ( Supplementary Fig. S8 ), our data suggested Notch1 loss promoted a more invasive phenotype due to the upregulation of genes important for invasion and migration. To further correlate Notch1 loss with tumor invasion, we assessed NOTCH1 expression in human head and neck cancers, cervical cancer, and breast cancers with defined preinvasive/less invasive and invasive lesions. As HPV-positive head and neck cancers rarely present with preinvasive disease, we assessed Notch1 expression in squamous cell carcinomas and exophytic verrucous carcinomas in retrospectively acquired head and neck specimens. Previous groups demonstrated that squamous cell carcinomas were associated with a more invasive phenotype and higher MMP expression while verrucous carcinomas were associated with less aggressive features and lower MMP expression (28) . From 14 verrucous carcinomas and 72 invasive squamous cell carcinomas, 85.7% of verrucous carcinomas (12 of 14) expressed moderate to high levels of Notch1 compared with 22.2% of invasive squamous cell carcinomas (16/72; P < 0.0001; Fig. 7A and B) . To extend these results to other HPVpositive and HPV-negative cancers, we assessed Notch1 expression in cervical and breast cancers, both of which present with clinically relevant preinvasive and invasive lesions. In cervical cancer, Notch1 and its transcriptional targets Hes1 and Hey1 were downregulated in invasive cervical cancers compared with preinvasive lesions (Fig. 7C) . Similarly, invasive breast cancer had lower Notch1 expression compared with normal breast tissue ( Fig. 7D) . Thus, changes in Notch1 expression in cervix, breast, and head and neck cancers supported our observations that loss of Notch1 resulted in a more invasive phenotype.
Discussion
Here, we identified several cellular genes that facilitated HPV carcinogenesis, including Notch1, which functioned unlike a traditional tumor suppressor or oncogene. Our observation that Notch1 activation promoted primary tumor growth contrasts with previous observations where Notch1 inhibited squamous carcinogenesis (29) . We draw our conclusions using both forward and reverse genetic approaches and, thereby, avoid the limitations of using a single model system. Because Notch1 gain or loss promoted the growth of tumors possessing the same driving mutations, the proto-oncogenic roles of Notch1 activation or loss occurs under similar genomic contexts. Furthermore, these genetically engineered mouse models avoided the impact of undefined genetic changes present during chemical carcinogenesis and/or in transplanted tumor models. In addition, we manipulated Notch1 activity in primary tumor models harboring defined oncogenic mutations that better reflects the genetic changes occurring in cancers. Finally, differences in Notch1 expression in human cancers and in HPV tumors undergoing insertional mutagenesis indicates that pathophysiologic activation or loss of Notch1 promoted distinct tumorigenic phenotypes. Therefore, tumors with multiple driving mutations, such as those associated with HPV, may negate the tumor-suppressive activities of Notch1 and allow dichotomous Notch1 expression to stimulate distinct progrowth pathways.
Although we used multiple models in which autochthonous tumors arose in mice with defined oncogenic events, our conclusions are limited by the intrinsic nature of any model system. First, the mixed genetic background could contribute to the manner by Fig. 1C . F, oral tumors were enriched for DNA replication and cell-cycle genes as determined by GSEA analysis. RNA from KHR (n ¼ 5) and KHR NICD (n ¼ 6) tumors was subjected to Illumina microarray analysis. A total of 18,138 genes were subjected to GSEA analysis. G, NICD expression did not affect differentiation of KHR oral tumors. KHR and KHR NICD oral tumors were stained for CK14 (green), which a SB insertion affects tumorigenesis, albeit by unknown mechanisms and undefined polymorphisms between C57BL/6 and FVB. For validation experiments, we used C57BL/6 and (C57BL/6xFVB)F1 mice with genetically defined backgrounds in order to avoid the impact of genetic differences on tumors possessing normal or altered Notch1 activity. In addition, our oral tumor models used a Kras G12D transgene that is infre- Finally, insertional mutagenesis in HPV transgenic mice relied on carcinogens to initiate tumorigenesis that differs from the clinical scenario, as HPV tumors do not often display signatures of mutagen exposure. Therefore, our observations using models with defined HPV oncogene expression and Kras mutations may be applicable to only a fraction of HNSCCs that possess these mutations.
Using transposon-based insertional mutagenesis, we identified 39 candidate genes associated with the development of HPVpositive cancers. Although 15 of these candidates were previously identified in models of Ras-induced papillomas (34), the physiologic role of these candidates remained uncertain as SB-insertional mutagenesis did not significantly affect tumorigenesis in that model. In contrast, tumor development in our model required HPV expression and/or SB-insertional mutagenesis. In addition, other studies involving SB insertional mutagenesis identified Usp9x and Arid1b as CIS in pancreatic adenocarcinomas (24) and medulloblastomas (35) , respectively. Consequently, we have identified 22 additional candidates involved in HPV carcinogenesis. These additional CIS may reflect our increased sequencing depth where we analyzed 273,054 unique sequence reads compared with 50 to 85,000 unique sequences in previous reports (15, 16) . As with transposon-based insertional mutagenesis, several groups have observed that the genomic integration of viral DNA may also drive carcinogenesis by inserting in proximity to known cancer-associated genes (3, (36) (37) (38) . Similar to these reports, we did observe transposon integrations in regions containing Lipc and Usp9x that were also targets for integration by the HPV genome in human cancers. Thus, we have identified known and novel candidates involved in HPV carcinogenesis that provided novel leads for how these genes affected tumor growth.
Our observation that Notch1 activation promoted primary tumor growth contrasts with previous observations where Notch1 inhibited squamous carcinogenesis. Classically, activating NOTCH1 mutations were observed in T-cell acute lymphocytic leukemia targeting the negative regulatory region (NRR, exons [26] [27] [28] as well as the inhibitory PEST domain (exon 34; Supplementary Fig. S9 ). In contrast, in HNSCC and other squamous cancers, inhibitory mutations have been identified in the ligand binding domain and the Ankryn repeat domains. However, potentially activating mutations in the NRR and PEST domains as well as in another regulatory region, Abruptex domain have been identified and are displayed in Supplementary Fig. S9 (2, 4, 39) . Although many of the transposon insertions that promoted Notch1 activity in our model did so most likely by inducing gene expression, five transposons integrated into introns 27 and 33 that also likely mimic the mutations in the NRR or PEST domains, respectively. Although transgenic expression of NICD accelerated HPV tumor growth, expression of the activated NICD in cultured keratinocytes or in neonatal mouse skin resulted in growth arrest and the induction of differentiation (25, 40) . Although these studies relied on models of normal skin differentiation, we observed that Notch1 promoted the growth of tumors containing additional driving mutations. Because loss of p21 WAF1/CIP or p16 INK4A also abrogated the growth-inhibitory properties of Notch1 in cultured keratinocytes (40, 41) , inhibition of such pathways by HPV and/or Kras oncogenes in our model likely enabled Notch1 to promote tumor growth. Such additional oncogenic mutations in cancers may explain the opposing actions of Notch1 as a tumor suppressor or oncogene in cultured HPV-positive cells (10, 11) . Namely, by impairing tumor differentiation, some oncogenes may enable other Notch1 functions to further enhance tumor growth. Thus, Notch1 may use multiple pathways to stimulate the growth of cancers harboring additional driving mutations.
Although we observed that loss of Notch1 promoted tumorigenesis consistent with previous reports (29, (42) (43) (44) , we also observed that the tumor genotype dictated the threshold level of Notch1 necessary to affect tumor growth. Namely, HPV-positive tumors grew faster with haploinsufficient or complete loss of Notch1. In contrast, HPV-negative tumors grew faster only with complete loss of Notch1 consistent with previous reports (29, 44) . Analysis of 279 HNSCCs from The Cancer Genome Atlas contained revealed that 46 of 197 HPV-negative cancers (18.9%) had at least loss of one Notch1 allele while HPV-positive cancers had 1 of 35 events (2.8%; P ¼ 0.005; ref. 30 ). Although we caution conclusions due to the imbalanced and limited sample sizes, these results are consistent with the model in which HPV oncogenes decrease the threshold of Notch1 loss necessary for carcinogenesis. HPV oncogenes may enable hemizygous loss of Notch1 to accelerate tumor growth via distinct mechanisms. Although cutaneous HPV oncogenes, such as HPV8 E6, may directly repress Notch1 activity (1, 45) , similar findings have not been reported for high-risk HPV16 oncogenes used in our model. In contrast, our observations suggest that HPV oncogenes may facilitate the activation of pathways involved in cell migration and invasion that complement the impact of Notch1 haploinsufficiency. Therefore, Notch1 haploinsufficiency in cancers harboring multiple oncogenic drivers may induce an invasive phenotype that is distinct from the role Notch1 activation plays in tumors.
In both forward and reverse genetic experiments, we observed that Notch1 gain or loss promoted the growth of HPV-positive tumors. In contrast, other reports indicated that Notch1 can function either as an oncogene as observed in T-cell acute lymphocytic leukemia (ALL; ref. 46 ) and pancreatic cancer (47) or as a tumor suppressor as observed in head and neck cancer (2, 4) and chronic myelogenous monocytic leukemia (48) among others. Previous groups sought to rectify these opposing Notch1 functions based on the ability of Notch1 to control differentiation depending on the tissue context (6, 49) . In our model, gain or loss of Notch1 promoted the growth of similar tumors that also harbored HPV and Kras oncogenes. Therefore, additional driving mutations that commonly occur in cancers may impair Notch1's ability to control cell fate and its resulting tumor-suppressive function. Thus, given the paradoxical actions of Notch1 in similar tumors, therapeutic strategies targeting the Notch pathway should account for the impact of additional driving mutations in cancers.
In conclusion, we identified several cellular genes that facilitated HPV carcinogenesis, including Notch1. The oncogenic role of Notch1 depended more on the tumor genotype than the tissue context that contrasts with the previous notions of tissue-specific functions for Notch1. Furthermore, activation or loss of Notch1 likely stimulated tumor growth through distinct pathways. Therefore, our results suggest that traditional tumor suppressors or oncogenes may function differently in the context of additional driving mutations and promote tumor growth via distinct pathways. Thus, interpreting gene function in the presence of additional driving mutations will enable us to better predict tumor behavior and to tailor therapies accordingly.
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